pah-protein

📖 Wiki Page

protein1502 wordssynced 2026-04-02

pah-protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">pah-protein</th>
</tr>
<tr>
<td class="label">Regulatory Mechanism</td>
<td>Effect on PAH Activity</td>
</tr>
<tr>
<td class="label">Phenylalanine concentration</td>
<td>Allosteric activation at high [Phe]</td>
</tr>
<tr>
<td class="label">Phosphorylation (Ser16)</td>
<td>Increases specific activity</td>
</tr>
<tr>
<td class="label">BH₄ availability</td>
<td>Absolute requirement for catalysis</td>
</tr>
<tr>
<td class="label">Hepatic phenylalanine levels</td>
<td>Diurnal variation in activity</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">151 edges</a></td>
</tr>
</table>

...

pah-protein

Introduction

Phenylalanine Hydroxylase (PAH) is a crucial enzyme in phenylalanine metabolism, catalyzing the rate-limiting step in the catabolic pathway that converts the essential amino acid L-phenylalanine to L-tyrosine [blau2010](https://pubmed.ncbi.nlm.nih.gov/21040663/). This iron-dependent, tetrahydrobiopterin (BH₄)-requiring enzyme is essential for maintaining phenylalanine homeostasis, and its dysfunction leads to phenylketonuria (PKU), the most common inherited metabolic disorder of amino acid metabolism.

PAH is expressed primarily in the liver, where it functions as a homotetramer to metabolize the majority of dietary phenylalanine. However, PAH is also expressed at lower levels in the kidney and brain, where its activity is critical for local tyrosine synthesis and neurotransmitter production [scriver2008](https://pubmed.ncbi.nlm.nih.gov/19051295/). The brain-specific isoform plays important roles in neuronal function, influencing the synthesis of dopamine, norepinephrine, and melanin precursors.

Beyond its well-established role in PKU, emerging research has revealed connections between altered phenylalanine metabolism and neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). Elevated phenylalanine levels and altered PAH activity have been documented in these conditions, suggesting potential roles in disease pathogenesis and offering novel biomarker possibilities [cacciola2016](https://pubmed.ncbi.nlm.nih.gov/26476835/).

This page provides a comprehensive overview of PAH's molecular structure, catalytic mechanism, physiological functions, and implications in both metabolic and neurodegenerative disorders.

Structure

Domain Architecture

PAH is a homotetrameric enzyme with each subunit consisting of approximately 507 amino acids and a molecular weight of ~52 kDa. The protein is organized into three distinct functional domains:

N-terminal Regulatory Domain (residues 1-110): Contains the phenylalanine-binding allosteric site that regulates enzyme activity in response to substrate concentration. This domain undergoes conformational changes that modulate the catalytic efficiency.

Catalytic Domain (residues 111-410): The central domain contains the iron-binding site and BH₄ binding pocket. The active site features a conserved iron-binding motif (His-Phe-Asp) that coordinates the ferrous iron (Fe²⁺) essential for catalysis [fitzpatrick1999](https://pubmed.ncbi.nlm.nih.gov/10354454/).

C-terminal Tetramerization Domain (residues 411-507): Mediates subunit assembly into the functional tetramer through hydrophobic interactions and salt bridges. Tetramer formation is required for optimal enzyme stability and activity.

Crystal Structure

The crystal structure of human PAH has been solved in multiple conformational states (PDB: 1PHZ, 2PAH, 1J8U), revealing:

The detailed architecture of the catalytic center
The BH₄ binding pocket and its interactions with the cofactor
The conformational changes accompanying substrate binding
The oligomerization interface at the C-terminus [vargas2019](https://pubmed.ncbi.nlm.nih.gov/31795380/)

Cofactor Requirements

PAH requires multiple cofactors for catalytic activity:

Ferrous Iron (Fe²⁺): The catalytic center contains a tightly bound iron ion that participates directly in the hydroxylation reaction
Tetrahydrobiopterin (BH₄): The essential cofactor that serves as both a reducing agent and participant in the catalytic cycle
Molecular Oxygen (O₂): Required as the oxidant for the hydroxylation reaction

Normal Function

Catalytic Mechanism

PAH catalyzes the conversion of L-phenylalanine to L-tyrosine through a complex oxidative reaction:

Overall Reaction:
L-Phenylalanine + O₂ + BH₄ → L-Tyrosine + H₂O + BH₂ (dihydrobiopterin)

The catalytic mechanism proceeds through several steps:

Substrate Binding: L-phenylalanine binds to the active site, displacing the regulatory domain and allowing access to the catalytic pocket

Oxygen Activation: BH₄ reduces molecular oxygen, generating a ferryl (Fe⁴⁺=O) intermediate

Hydroxylation: The ferryl species attacks the aromatic ring of phenylalanine at the para position

Product Release: L-tyrosine is released, and BH₄ is regenerated from BH₂ by dihydropteridine reductase [fitzpatrick1999](https://pubmed.ncbi.nlm.nih.gov/10354454/)

Regulation

PAH activity is tightly regulated through multiple mechanisms:

Physiological Role

In the liver, PAH functions as part of the phenylalanine catabolic pathway that prevents accumulation of this potentially neurotoxic amino acid. The tyrosine produced serves as:

Precursor for catecholamine neurotransmitters (dopamine, norepinephrine)
Substrate for melanin synthesis
Component in protein synthesis
Precursor for thyroid hormone (T₃, T₄)

In the brain, local tyrosine synthesis by neuronal PAH supports neurotransmitter production independent of peripheral tyrosine pools [jhorvat2016](https://pubmed.ncbi.nlm.nih.gov/26802174/).

Role in Disease

Phenylketonuria (PKU)

PAH deficiency is the genetic cause of phenylketonuria, an autosomal recessive disorder affecting approximately 1 in 10,000-15,000 births worldwide [blau2010](https://pubmed.ncbi.nlm.nih.gov/21040663/).

Genetics: Over 600 pathogenic variants have been identified in the PAH gene, including:

Missense mutations (most common, ~60%)
Nonsense mutations (~15%)
Splice-site mutations (~15%)
Small deletions/insertions (~10%)

Pathophysiology: Loss of PAH activity leads to:

Accumulation of phenylalanine in blood and tissues
Deficiency of tyrosine and downstream metabolites
Direct neurotoxicity of elevated phenylalanine
Impaired transport of other amino acids across the blood-brain barrier

Clinical Features:

Intellectual disability (if untreated)
Microcephaly
Seizures
Eczema
Musty odor
Hypopigmentation

Treatment:

Lifelong phenylalanine-restricted diet [matalon2004](https://pubmed.ncbi.nlm.nih.gov/15507178/)
Sapropterin dihydrochloride (BH₄) supplementation for responsive patients [levy2007](https://pubmed.ncbi.nlm.nih.gov/17236790/)
Pegvaliase (PEGylated phenylalanine ammonia lyase) for adults
Gene therapy under clinical investigation

Alzheimer's Disease

Altered phenylalanine metabolism has been documented in Alzheimer's disease:

Findings:

Elevated plasma phenylalanine levels in AD patients compared to controls [cacciola2016](https://pubmed.ncbi.nlm.nih.gov/26476835/)
Reduced tyrosine availability affecting catecholamine synthesis
Altered BH₄ metabolism impacting neuronal function
Association between elevated phenylalanine and disease severity

Potential Mechanisms:

Phenylalanine-induced oxidative stress in neurons
Impaired neurotransmitter synthesis contributing to cognitive decline
Dysregulation of one-carbon metabolism
Competition with other large neutral amino acids for transport

Parkinson's Disease

Findings:

Altered phenylalanine metabolism in PD patients
Elevated phenylalanine:tyrosine ratio as potential biomarker
Impaired BH₄ synthesis affecting dopaminergic neurons
Interaction with levodopa treatment response

Research Implications:

Phenylalanine tolerance may vary in PD
Nutritional interventions targeting amino acid balance
Monitoring phenylalanine in patients undergoing dopaminergic therapy

Other Conditions

Tyrosinemia: Secondary to severe PAH deficiency
Hyperphenylalaninemia: Broader category including BH₄ deficiencies
Maternal PKU: Teratogenic effects on fetus during pregnancy

Therapeutic Implications

Pharmacological Approaches

Sapropterin Dihydrochloride (BH₄):

Synthetic cofactor that can stabilize mutant PAH enzymes
Effective in approximately 30-50% of PKU patients
Requires loading dose followed by maintenance therapy [levy2007](https://pubmed.ncbi.nlm.nih.gov/17236790/)

Pegvaliase (PEG-PAL):

PEGylated phenylalanine ammonia lyase
Converts phenylalanine to trans-cinnamic acid and ammonia
Administered via subcutaneous injection
Approved for adults with PKU

Pharmacological Chaperones:

Small molecules that stabilize mutant PAH protein
Increase residual enzyme activity
Under clinical investigation

Gene Therapy

AAV-mediated PAH gene delivery has shown promise in preclinical models:

Correction of metabolic abnormalities in PAH-deficient mice
Sustained expression of functional enzyme
Potential for single-dose treatment
Clinical trials ongoing

Dietary Management

The cornerstone of PKU treatment remains dietary phenylalanine restriction:

Natural protein restriction
Phe-free amino acid supplements
Special low-protein medical foods
Monitoring of blood Phe levels [longo2004](https://pubmed.ncbi.nlm.nih.gov/15557116/)

Summary

Phenylalanine Hydroxylase (PAH) is an essential enzyme in phenylalanine catabolism, catalyzing the conversion of phenylalanine to tyrosine. Loss-of-function mutations in PAH cause phenylketonuria (PKU), the most common inborn error of metabolism, characterized by neurotoxic phenylalanine accumulation and, without treatment, severe neurological damage. The enzyme requires ferrous iron and tetrahydrobiopterin (BH₄) as cofactors, and its activity is regulated by substrate concentration and post-translational modifications.

Beyond its central role in PKU, emerging evidence links altered phenylalanine metabolism to neurodegenerative diseases. Elevated phenylalanine levels have been documented in Alzheimer's disease and Parkinson's disease, where they may contribute to disease pathogenesis through oxidative stress, impaired neurotransmitter synthesis, and metabolic dysregulation. Understanding PAH function and its connections to neurodegeneration offers insights into disease mechanisms and potential therapeutic approaches.

References

[Blau N et al., Phenylketonuria (2010)](https://pubmed.ncbi.nlm.nih.gov/21040663/)

[Scriver CR, Kaufman S, Hyperphenylalaninemia: phenylalanine hydroxylase deficiency (2008)](https://pubmed.ncbi.nlm.nih.gov/19051295/)

[Fitzpatrick PF, The tetrahydropterin-dependent amino acid hydroxylases (1999)](https://pubmed.ncbi.nlm.nih.gov/10354454/)

[Güttler F, Guldberg P, The influence of mutations on enzyme activity and phenotype in phenylketonuria (2000)](https://pubmed.ncbi.nlm.nih.gov/10693647/)

[Anderson PJ et al., Neuropsychological functioning in children with phenylketonuria (2008)](https://pubmed.ncbi.nlm.nih.gov/18214867/)

[Matalon R, Michals-Matalon K, Recent advances in treatment of phenylketonuria (2004)](https://pubmed.ncbi.nlm.nih.gov/15507178/)

[Levy H et al., Recommendations for loading doses of sapropterin dihydrochloride (2007)](https://pubmed.ncbi.nlm.nih.gov/17236790/)

[Longo N et al., Long-term follow-up of patients with phenylketonuria (2004)](https://pubmed.ncbi.nlm.nih.gov/15557116/)

[Wettstein S et al., History of phenylketoneuria and hyperphenylalaninemia (2015)](https://pubmed.ncbi.nlm.nih.gov/26666963/)

[Vargas M et al., Phenylalanine hydroxylase: structure and function (2019)](https://pubmed.ncbi.nlm.nih.gov/31795380/)

[Jhorvat R et al., Tyrosine and cognitive function in PKU (2016)](https://pubmed.ncbi.nlm.nih.gov/26802174/)

[Cacciola A et al., Phenylalanine and brain function in aging (2016)](https://pubmed.ncbi.nlm.nih.gov/26476835/)

📖 View canonical wiki page →

pah-protein

pah-protein

Introduction

pah-protein

Introduction

Structure

Domain Architecture

Crystal Structure

Cofactor Requirements

Normal Function

Catalytic Mechanism

Regulation

Physiological Role

Role in Disease

Phenylketonuria (PKU)

Alzheimer's Disease

Parkinson's Disease

Other Conditions

Therapeutic Implications

Pharmacological Approaches

Gene Therapy

Dietary Management

Summary

See Also

References